3-drug combo for untreated NK/T-cell lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have a confirmed diagnosis of extranodal NK/T-cell lymphoma (ENKTL).
- You must have at least one risk factor, such as being over 60, having B symptoms (like fever, night sweats, or weight loss), needing some help with daily activities (ECOG 2 or higher), high LDH, or high EBV-DNA levels.
- Your bone marrow, liver, and heart must be working well enough (based on blood tests and heart function).
- You cannot have active infections, heart problems within the last 6 months, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
This trial tests a new drug, selinexor, combined with a lower dose of radiation for people with early-stage extranodal NK/T-cell lymphoma that started in the nose or upper throat. The goal is to see if this combination works well and has fewer side effects.
This trial compares a new targeted drug combined with standard chemotherapy and an immunotherapy drug against the standard chemo-immunotherapy alone, for people with advanced or non-nasal NK/T-cell lymphoma who haven't been treated yet. The goal is to see if adding the targeted drug improves outcomes.
This study tests a new medicine called sugemalimab (an immunotherapy that helps your immune system fight cancer) combined with a chemotherapy regimen (PGemOx) for people with a rare type of lymphoma that has come back or not responded to previous treatment. The study could help you see if this combination works better than the placebo (inactive) plus the same chemotherapy.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
Hear when a new Extranodal NK/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.